Indication:

Linlid is indicated for Skin & skin structure infections especially in Diabetic Foot Infections (DFIs),

Nosocomial pneumonia, Community-acquired pneumonia & Vancomycin-resistant Enterococcus faecium

Infections.

Dosage & Administration:

For Pediatric patient (Birth through 11 years of age) Complicated skin & skin structure infections,

Community-acquired pneumonia & Nosocomial pneumonia, Vancomycin-resistant Enterococcus faecium

Infections: 10 mg/kg t.i.d

Uncomplicated skin & skin structure infections: < 5>

For Adult patient Complicated skin & skin structure infections, Community-acquired pneumonia &

Nosocomial pneumonia: 600 mg b.i.d 10 to 14 days.

Vancomycin resistant Enterococcus faecium infections: 600 mg b.i.d 14 to 28 days.

Uncomplicated skin & skin structure infections: 400 mg b.i.d 10 to 14 days.

Preparation:

Linlid^® 400 Tablet: Each box containing 2×10’s tablets in blister pack.

Linlid^® 600 Tablet: Each box containing 1×10’s tablets in blister pack.

Linlid^® Suspension: Each bottle containing dry powder for reconstitution into 100 ml suspension with a

Measuring cup.